SlideShare una empresa de Scribd logo
1 de 61
Screening of Anxiolytic Agents in
Drug Discovery
For MD Pharmacology
Dr. Advaitha M V
Anxiety Disorders
• Definition : Anxiety is defined as a subjective
sense of unease, dread, or foreboding.
• It is the most prevalent psychiatric illnesses in
the general community, are present in 15–20%
of medical clinic patients.
Preclinical anxiety models
• The goal of anxiety models is to produce a
form of abnormally elevated anxiety.
• It should more closely resemble, by
definition, the pathological nature of human
anxiety disorders.
• Anxiety models are Models that generate
lasting or permanently heightened anxiety.
This can be achieved by acutely or chronically
subjecting animals to stressors before testing.
 OR identifying genetic populations (inbred
and selectively bred strains) or engineering
mutant mice with innate anxiety-like
phenotypes.
• This approach has proven to be valuable for
screening novel anxiolytics and testing the
pharmaco selectivity of putative anxiolytics .
• Emerging genetic technology is the
optogenetics. It will be integral to future basic
anxiety research.
Optogenetics
• It is the combination of genetic and optical methods
to control specific events in targeted cells of living
tissue in the millisecond timescale.
• Optogenetic approaches have been used to map
neural circuits in the amygdala that contribute to fear
conditioning.
• However , in general , it is only simple tests or
assays which transiently evoke an anxiety-like
behaviour in rhodents is commonly employed.
The five main anxiety disorders with preclinical
tests which resembles human anxiety
• Generalized anxiety disorder (GAD)----MOST
OF THE TESTS
• Post-traumatic stress disorder (PTSD)…….
FEAR CONDITIONED TESTS
• Panic disorder………… ELEVATED T MAZE
MODEL and MOUSE DEFENSE TEST BATTERY
• Obsessive compulsive disorder (OCD)……
???????
• Social anxiety disorder (SAD)…… SOCIAL
INTERACTION MODEL
PRECLINICAL EVALUATION OF
ANXIOLYTICS
• In-vitro Methods
• In-vivo Methods
• Our main focus here would be In-vivo.
In- vitro methods
• GABAA receptor binding
• GABAB receptor binding
• Benzodiazepine receptor: [3H]-flunitrazepam
binding assay
• Serotonin (5-HT1A) receptor: binding of [3H]-8-
hydroxy-2-(di-n-propylamino)-tetralin ([3H]-
DPAT)
• Serotonin (5-HT1B) receptors in brain: binding
of [3H]5-hydroxytryptamine ([3H]5-HT)
The following parameters are calculated:
• Total binding
• Non-specific binding
• Specific binding= total binding– non-specific
binding.
In Vivo Methods
Validity
• Face validity : A feature that is assessed (for a
test or model of anxiety) by determining how
closely the model or test resembles human
anxiety symptoms .
• Predictive validity : whether the model or
test reliably responds to clinically efficacious
anti- anxiety medications .
• Construct validity : whether the degree to
which the model or test recruits the same
underlying neurobiology as implicated in
human anxiety .
Elevated plus –maze (EPM) test
This has widely validated to measure anxiety to
rodents
Principle :
• The test is based on the natural aversion of
mice for open and elevated areas, as well as
• natural aversion on their natural spontaneous
exploratory behavior in novel environments.
• The apparatus consists of open arms and
closed arms, crossed in the middle
perpendicularly to each other, and a center
area.
• Mice are given access to all of the arms and
are allowed to move freely between them.
Evaluation :
• The number of entries into the open arms.
(Entry an arm is defined as animal placing all
four paws onto the arm. All tests are taped by
using a video camera)
• The time spent in the open arms are used as
indices of open space-induced anxiety.
Anxiolytic drugs specifically increase the
number of entries into the open arms and the
time spent there
Anxiogenic drugs specifically decrease the
entry
• The total entries score and total distance are
considered a
Useful index of general activity.
The percentages of entries and time spent in
each arm constitute the index of primary
anxiety
Methodology :
• The rats (200–250 g body weight) are housed
in pairs for 10 days prior to testing in the
apparatus.
• During this time the rats are handled by the
investigator on alternate days to reduce stress.
• 6 rats are taken for each group.
• Thirty min after i.p. administration of the test
drug or the standard, the rat is placed in the
center of the maze facing one of the enclosed
arms.
• Duration of test is 5 min where all data is
collected.
• Test should be conducted in sound proof
room.
• After each test, the maze is carefully cleaned
up with wet tissue paper (10% ethanol
solution)
• Anxiolytic treatments do not by
themselves increase exploration
in the tests but they decrease the
stress-induced inhibition of
exploration behaviour
light-dark Exploration model
• Crawley and goodwin (1980)
• Mice and rats tend to explore novel
environment ,but retreat from brightly lit
open field.
• In a two chambered system, where animal can
freely move between brightly lit open field
and dark corner, they show more crossings
between two chambers and more locomotor
activity after treatment with anxiolytics.
Methodology
• Test apparatus- light and dark chamber
divided by photocell equipped zone.
• Polypropylene animal cage 44x21x21 cm,
darkened with black spray over on-third of
surface.
• Partition containing 13cm long x 5cm high
opening separates the dark one third from
bright two thirds of the cage
• Cage rests on an animex activity monitor,
which counts the locomotor activity.
• Four sets of photocells across the partition,
automatically counts movement through the
partition and clocks time spent in light and
dark
• Naïve male mice or rats are placed in cage
• Animals are treated 30 min before the
experiment with test or vehicle
intraperitoneally and are observed for 10 min.
• Groups of 6-8 animals are used for each dose.
• Evaluation: number of crossings through the
partition between the light and dark chamber
are compared with total activity counts during
10 min
• Critical assessment of the method: anxiolytics
like diazepam, pentobarbital, meprobamate,
produce dose dependent increase in crossings
• Test is relatively simple with no painful stimuli
Social interaction in rats
• Purpose and rationale : In an unfamiliar and
brightly lit environment, the normal social
interaction of rats ( sniffing, nipping,
grooming) is suppressed.
• Anxiolytics counteract this suppression.
Procedure:
• Male sprague-dawley rats (225-275g) are
housed in groups of 5 animals
• Apparatus: perspex open-topped box (51x51x
20cm) with 17x17cm marked areas on the
floor.
• One hour prior to the test, 2 naïve rats from
separate housing cages are treated with test
compound orally
• They are placed into the box (with 60W bright
illumination 17cm above) and their behaviour
is observed over a 10 min period.
• 2 types of behaviour can be noted:
• Social interaction between the animals is
determined by timing the sniffing of partner,
crawling under or climbing over partner and
following partner.
• Exploratory motion is measured as the
number of crossings of the lines marked on
the floor of the test box.
• Six pairs are used for each dose
• Evaluation: values of treated partners are
compared with the data from 6 pairs of
untreated animals using single factor analysis
of variance followed by Dunnett’s t-test
• Open-field Test
• This test, originally designed by Hall on rats.
• It consists of placing an animal in an unknown
environment with surrounding walls, so as to
observe a number of behaviour patterns,
including
The tendency to stay on the periphery of the
field without entering the centre (called
thigmotaxis and often interpreted as anxious
behaviour)
 level of defecation and urination.
• The open field floor is divided into squares
• Animals are tested individually, always being
placed in the same position.
• Duration of test is usually 5 min.
• Higher levels of anxiety should mainly lead to
decreases in the ratio ‘number of squares
visited in centre/number of squares visited on
periphery.
• Anxiolytic agents should lead to increase in
this ratio
Vogel water-lick conflict test
• This test is a well-known method used in rats,
designed by Vogel et al.
• Recently, this test has been reported to
successfully detect anxiolytic-like action of
diazepam .
• In this test, thirsty animals gain water reward
through a water spout, but at the expense of
receiving a mild electric shock delivered to the
tongue.
• Licking in untreated/controls is suppressed
due to the conflict.
• Anxiolytics release this suppressed behaviour
and decrease the conflict.
• Diazepam and pentobarbital produces a
significant anti-conflict effect, which means
that -
These drugs increases the number of electric
shocks the mice received during the test
session.
• But drugs like baclofen, buspirone,
chlorpromazine and also haloperidol did not
produce anti-conflict effects.
Resident-intruder aggression test
Purpose and rational: To study the effects of
drugs in a test for offensive aggression, the
isolation-induced resident intruder aggression
model in the rat.
• Procedure: Sprague-Dawley rats weighing 250
to 450 g are housed in a light-dark (12L:12D)-,
temperature (ca. 22°C)- and humidity (ca.
55%)-controlled room.
Resident male rats (about 450 g) are tested in
their home cages for aggression against a
smaller (250 g) male intruder
• They are treated by intraperitoneal injection
of test drug or saline 15 min before the test.
• The resident female is removed from the cage
30 min prior to the start of the test period.
• After placing the intruder rat in the territorial
cage, the behavior of the resident male is
observed.
• The time until the first attack (in seconds),
number of attacks, and duration of each
attack (in seconds) are recorded for the next
15 min by a blind observer.
• Different behavioral elements are scored and
grouped into 7 behavioral categories:
offensive, exploration, social interest,
inactivity, avoidance, body care, defense.
• Evaluation: Paired and unpaired t-tests are
used for comparisons of means of absolute
values
Other Anti- Aggressive tests
• FOOT- SHOCK INDUCED AGGRESSION IN MICE
• ISOLATION INDUCED AGGRESSION
• MATERNAL AGGRESSION IN RATS
Anticipatory anxiety in mice
• Purpose and rationale: when group-housed
mice are removed one by one from their
home cage, the last mice removed have
always higher rectal temperatures than those
removed first.
• This phenomenon is caused by anticipatory
fear for an aversive event .
• Increase in temperature prevented by prior
treatment with diazepam and buspirone
• Procedure: groups of 18 male albino swiss
mice ( 25-30g) are housed in constant room
temperature and relative humidity, for atleast
7days.
• Test drugs or standard (diazepam) are
administered orally in various doses to groups
of 18 mice prior to the test.
• Thirty min later, first 3 mice are removed from
the cage, rectal temperature recorded by
inserting a silicone lubricated thermistor
probe (2mm diam)
• Average temperature of these 3 mice is taken
as basal value
• Mice number 4 to 15 are simply removed and
again returned to the cage.
• Thereafter body temperature is determined in
the remaining three animals.
• The difference of the mean value of these
mice and the basal values is calculated as
increase.
• Vehicle treated test groups display increases
of 1.1 to 1.3 °C.
• The mean increase values of treated groups
are compared by ANOVA statistics with the
controls .
mCPP induced anxiety in rats
• Purpose and rational: The metabolite of the
antidepressant drug trazodone is
1- (3-chlorphenyl)piperazine (= mCPP).
• It is 5- HT1C/1B/2C agonist.
• It has been shown to be anxiogenic both in
man and in rats.
• The compound induces hypophagia and
hypolocomotion, inhibits social interaction in
rats, diminishes exploratory activity of rats in
the open field test
• In the light-dark box test induces
hyperthermia
• Antagonism against these symptoms has been
proposed as a screening model for anxiolytic
drugs.
Novelty-suppressed feeding
• Purpose and rational: Placing a hungry rat
into an unfamiliar environment with access to
food results in a suppression of feeding
behavior relative to the condition when the
test environment is familiar.
• This effect has been termed hyponeophagia
and occurs because of the novelty of the test
environment.
• The avoidance of novel foods is termed food
neophobia
• Both hyponeophagia and food neophobia
have been assumed to measure emotionality
or anxiety by eliciting a conflict situation
arising from a fear of the novel setting and
foods, and the drive to eat.
Video downloads
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2
762911/bin/jove-22-1088.flv
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3
731199/bin/jove-77-4367.mov
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3
727206/bin/jove-76-50324.mov
Thank you

Más contenido relacionado

La actualidad más candente

Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugsBindu Pulugurtha
 
Screening of antihypertensive agents
Screening of antihypertensive agentsScreening of antihypertensive agents
Screening of antihypertensive agentsKanthlal SK
 
Screening of antiepileptic drugs
Screening of antiepileptic drugsScreening of antiepileptic drugs
Screening of antiepileptic drugsKanthlal SK
 
Screening model for asthma COPD
Screening model for asthma COPDScreening model for asthma COPD
Screening model for asthma COPDJaineel Dharod
 
Preclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic DrugsPreclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic DrugsShubham Kolge
 
Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan Divya Krishnan
 
Screening of antipyretic drugs
Screening of antipyretic drugsScreening of antipyretic drugs
Screening of antipyretic drugsSindhoora Shetty
 
Screening Models of Antidepressants Drugs
Screening Models of Antidepressants DrugsScreening Models of Antidepressants Drugs
Screening Models of Antidepressants DrugsKomalSingh301
 
Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents Anurag Chourasia
 
Screening of ANTIFERTILITY AGENTS and APHRODISIACS
Screening of ANTIFERTILITY AGENTS and APHRODISIACSScreening of ANTIFERTILITY AGENTS and APHRODISIACS
Screening of ANTIFERTILITY AGENTS and APHRODISIACSHimaniTailor
 
Screening models for inflammatory drugs
Screening models for inflammatory drugsScreening models for inflammatory drugs
Screening models for inflammatory drugsMy_VivJaan
 
pre clinical Screening for anti asthmatic drugs
pre clinical Screening  for anti asthmatic drugspre clinical Screening  for anti asthmatic drugs
pre clinical Screening for anti asthmatic drugsDHINESHKUMAR V
 
Screening models on aphrodisiac agents
Screening models on aphrodisiac agentsScreening models on aphrodisiac agents
Screening models on aphrodisiac agentsJaineel Dharod
 
Drug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agentsDrug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agentsDr. Abhishek Vyas
 
Preclinical screening of anti fertility agents
Preclinical screening of anti fertility agentsPreclinical screening of anti fertility agents
Preclinical screening of anti fertility agentsNaveen K L
 
Screening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseScreening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseAnupam dubey
 
Screening of Anti depressant
Screening of Anti depressantScreening of Anti depressant
Screening of Anti depressantPRIYAPN6
 
SCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docx
SCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docxSCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docx
SCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docxTUSHARUNDHAD3
 

La actualidad más candente (20)

Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugs
 
Screening of antihypertensive agents
Screening of antihypertensive agentsScreening of antihypertensive agents
Screening of antihypertensive agents
 
Screening of antiepileptic drugs
Screening of antiepileptic drugsScreening of antiepileptic drugs
Screening of antiepileptic drugs
 
Screening model for asthma COPD
Screening model for asthma COPDScreening model for asthma COPD
Screening model for asthma COPD
 
Preclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic DrugsPreclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic Drugs
 
Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan
 
Screening of antipyretic drugs
Screening of antipyretic drugsScreening of antipyretic drugs
Screening of antipyretic drugs
 
Screening Models of Antidepressants Drugs
Screening Models of Antidepressants DrugsScreening Models of Antidepressants Drugs
Screening Models of Antidepressants Drugs
 
Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents
 
Screening of ANTIFERTILITY AGENTS and APHRODISIACS
Screening of ANTIFERTILITY AGENTS and APHRODISIACSScreening of ANTIFERTILITY AGENTS and APHRODISIACS
Screening of ANTIFERTILITY AGENTS and APHRODISIACS
 
Screening of antidepressant
Screening of antidepressantScreening of antidepressant
Screening of antidepressant
 
Screening of antiparkinsonian agents
Screening of antiparkinsonian agentsScreening of antiparkinsonian agents
Screening of antiparkinsonian agents
 
Screening models for inflammatory drugs
Screening models for inflammatory drugsScreening models for inflammatory drugs
Screening models for inflammatory drugs
 
pre clinical Screening for anti asthmatic drugs
pre clinical Screening  for anti asthmatic drugspre clinical Screening  for anti asthmatic drugs
pre clinical Screening for anti asthmatic drugs
 
Screening models on aphrodisiac agents
Screening models on aphrodisiac agentsScreening models on aphrodisiac agents
Screening models on aphrodisiac agents
 
Drug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agentsDrug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agents
 
Preclinical screening of anti fertility agents
Preclinical screening of anti fertility agentsPreclinical screening of anti fertility agents
Preclinical screening of anti fertility agents
 
Screening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseScreening Methods of Parkinson's Disease
Screening Methods of Parkinson's Disease
 
Screening of Anti depressant
Screening of Anti depressantScreening of Anti depressant
Screening of Anti depressant
 
SCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docx
SCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docxSCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docx
SCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docx
 

Destacado

Screening methods of anxiolytics
Screening methods of anxiolyticsScreening methods of anxiolytics
Screening methods of anxiolyticsJitendra Agrawal
 
Anxiolytic drugs : important
Anxiolytic drugs : importantAnxiolytic drugs : important
Anxiolytic drugs : importantrx_sonali
 
Anxiolytic drugs
Anxiolytic drugsAnxiolytic drugs
Anxiolytic drugsUmair hanif
 
screening of anxiolytics
screening of anxiolyticsscreening of anxiolytics
screening of anxiolyticsSayanti Sau
 
Animal models for screening of antiepileptic drugs &
Animal models for screening of antiepileptic drugs &Animal models for screening of antiepileptic drugs &
Animal models for screening of antiepileptic drugs &kamal_1981
 
Anxiolytic screening models_utkarsh
Anxiolytic screening models_utkarshAnxiolytic screening models_utkarsh
Anxiolytic screening models_utkarshUtkarsh Alok
 
Preclinical screening methods of Sedative and hypnotics by syed
Preclinical screening methods of Sedative and hypnotics by syedPreclinical screening methods of Sedative and hypnotics by syed
Preclinical screening methods of Sedative and hypnotics by syedMubasheer syed
 
Screening procedure for amnesia
Screening procedure for amnesiaScreening procedure for amnesia
Screening procedure for amnesiaJathin Menon
 
Animal models of depression and anxiety
Animal models of depression and anxiety Animal models of depression and anxiety
Animal models of depression and anxiety Asmae LGUENSAT
 
Research Methods - Anxiolytic Activity of Alugbati
Research Methods - Anxiolytic Activity of AlugbatiResearch Methods - Anxiolytic Activity of Alugbati
Research Methods - Anxiolytic Activity of AlugbatiEnzo Engada
 
Presentation on experimental evaluation of memory enhancers
Presentation on experimental evaluation of memory enhancersPresentation on experimental evaluation of memory enhancers
Presentation on experimental evaluation of memory enhancersAkhil Agarwal
 
Anti-arrhythmic evaluation
Anti-arrhythmic evaluationAnti-arrhythmic evaluation
Anti-arrhythmic evaluationDr. POOJA VAIDYA
 
Neuropharmacology: Methods
Neuropharmacology: MethodsNeuropharmacology: Methods
Neuropharmacology: MethodsBrian Piper
 

Destacado (20)

Screening methods of anxiolytics
Screening methods of anxiolyticsScreening methods of anxiolytics
Screening methods of anxiolytics
 
Anxiolytic drugs : important
Anxiolytic drugs : importantAnxiolytic drugs : important
Anxiolytic drugs : important
 
Antianxiety drugs
Antianxiety drugsAntianxiety drugs
Antianxiety drugs
 
Anxiolytic drugs
Anxiolytic drugsAnxiolytic drugs
Anxiolytic drugs
 
screening of anxiolytics
screening of anxiolyticsscreening of anxiolytics
screening of anxiolytics
 
Aminal models for seizure
Aminal models for seizureAminal models for seizure
Aminal models for seizure
 
Animal models for screening of antiepileptic drugs &
Animal models for screening of antiepileptic drugs &Animal models for screening of antiepileptic drugs &
Animal models for screening of antiepileptic drugs &
 
Anxiolytic screening models_utkarsh
Anxiolytic screening models_utkarshAnxiolytic screening models_utkarsh
Anxiolytic screening models_utkarsh
 
Preclinical screening methods of Sedative and hypnotics by syed
Preclinical screening methods of Sedative and hypnotics by syedPreclinical screening methods of Sedative and hypnotics by syed
Preclinical screening methods of Sedative and hypnotics by syed
 
Screening procedure for amnesia
Screening procedure for amnesiaScreening procedure for amnesia
Screening procedure for amnesia
 
Animal models of depression and anxiety
Animal models of depression and anxiety Animal models of depression and anxiety
Animal models of depression and anxiety
 
Glaucoma 2011
Glaucoma   2011 Glaucoma   2011
Glaucoma 2011
 
Research Methods - Anxiolytic Activity of Alugbati
Research Methods - Anxiolytic Activity of AlugbatiResearch Methods - Anxiolytic Activity of Alugbati
Research Methods - Anxiolytic Activity of Alugbati
 
Presentation on experimental evaluation of memory enhancers
Presentation on experimental evaluation of memory enhancersPresentation on experimental evaluation of memory enhancers
Presentation on experimental evaluation of memory enhancers
 
Anti-arrhythmic evaluation
Anti-arrhythmic evaluationAnti-arrhythmic evaluation
Anti-arrhythmic evaluation
 
Antistress
AntistressAntistress
Antistress
 
Glaucoma Review by Dr. Allen
Glaucoma Review by Dr. AllenGlaucoma Review by Dr. Allen
Glaucoma Review by Dr. Allen
 
pharmacogenomics by rajesh .I
pharmacogenomics by rajesh .Ipharmacogenomics by rajesh .I
pharmacogenomics by rajesh .I
 
Neuro pharmacologie
Neuro pharmacologie Neuro pharmacologie
Neuro pharmacologie
 
Neuropharmacology: Methods
Neuropharmacology: MethodsNeuropharmacology: Methods
Neuropharmacology: Methods
 

Similar a Screening of Anxiolytics

Screening Methods of Anti Anxiety Agents
Screening Methods of Anti Anxiety AgentsScreening Methods of Anti Anxiety Agents
Screening Methods of Anti Anxiety AgentsAnupam dubey
 
Screening of anxiolytic agents
Screening of anxiolytic agents Screening of anxiolytic agents
Screening of anxiolytic agents yasmeenmir1
 
ANXIOLYTICS.pptx
ANXIOLYTICS.pptxANXIOLYTICS.pptx
ANXIOLYTICS.pptxAdarshGaur8
 
Screening of analgesics
Screening of analgesics Screening of analgesics
Screening of analgesics Asma Ashraf
 
Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines Sagar Dalvi
 
Screening Models of Alzheimers disease.pptx
Screening Models of Alzheimers disease.pptxScreening Models of Alzheimers disease.pptx
Screening Models of Alzheimers disease.pptxArchna53
 
CNS stimulant & depressant models
CNS stimulant & depressant modelsCNS stimulant & depressant models
CNS stimulant & depressant modelsdhruvipatel3790
 
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).helasri gummadi
 
Hypnotics Screening Methods by Tarun Biswas
Hypnotics Screening Methods by Tarun BiswasHypnotics Screening Methods by Tarun Biswas
Hypnotics Screening Methods by Tarun BiswasTarun Biswas
 
Preclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activityPreclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activityShrutiGautam18
 
Screening methods for Analgesics
Screening methods for AnalgesicsScreening methods for Analgesics
Screening methods for AnalgesicsFoziyaKhan
 
Screening models(IN-VIVO) for analgesics and anti inflammatory agents
Screening models(IN-VIVO) for analgesics and anti inflammatory agentsScreening models(IN-VIVO) for analgesics and anti inflammatory agents
Screening models(IN-VIVO) for analgesics and anti inflammatory agentsMADHAV JAJNURE
 
Screening models of alzheimer’s disease
Screening models of alzheimer’s disease Screening models of alzheimer’s disease
Screening models of alzheimer’s disease VishnuPrabhakar26
 
Antipsychotic screening models
Antipsychotic screening modelsAntipsychotic screening models
Antipsychotic screening modelsInnocentAmubwine
 
Acute oral Toxicity Up-Down Procedure 425 guideline
Acute oral Toxicity Up-Down Procedure 425 guidelineAcute oral Toxicity Up-Down Procedure 425 guideline
Acute oral Toxicity Up-Down Procedure 425 guidelineDikuNath
 
Acute toxicity studies-425
Acute toxicity studies-425Acute toxicity studies-425
Acute toxicity studies-425jeshicabulsara
 

Similar a Screening of Anxiolytics (20)

Screening Methods of Anti Anxiety Agents
Screening Methods of Anti Anxiety AgentsScreening Methods of Anti Anxiety Agents
Screening Methods of Anti Anxiety Agents
 
Screening of anxiolytic agents
Screening of anxiolytic agents Screening of anxiolytic agents
Screening of anxiolytic agents
 
ANXIOLYTICS.pptx
ANXIOLYTICS.pptxANXIOLYTICS.pptx
ANXIOLYTICS.pptx
 
Screening methods
Screening methodsScreening methods
Screening methods
 
Screening of analgesics
Screening of analgesics Screening of analgesics
Screening of analgesics
 
Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines Acute Toxicity by OECD Guidelines
Acute Toxicity by OECD Guidelines
 
Screening Models of Alzheimers disease.pptx
Screening Models of Alzheimers disease.pptxScreening Models of Alzheimers disease.pptx
Screening Models of Alzheimers disease.pptx
 
CNS stimulant & depressant models
CNS stimulant & depressant modelsCNS stimulant & depressant models
CNS stimulant & depressant models
 
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
Oecd acute,subacte, sub chronic dermal toxicity studies(402, 410, 411).
 
Hypnotics Screening Methods by Tarun Biswas
Hypnotics Screening Methods by Tarun BiswasHypnotics Screening Methods by Tarun Biswas
Hypnotics Screening Methods by Tarun Biswas
 
Preclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activityPreclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activity
 
Screening methods for Analgesics
Screening methods for AnalgesicsScreening methods for Analgesics
Screening methods for Analgesics
 
Anxiolytics screening methods
Anxiolytics screening methodsAnxiolytics screening methods
Anxiolytics screening methods
 
Screening models(IN-VIVO) for analgesics and anti inflammatory agents
Screening models(IN-VIVO) for analgesics and anti inflammatory agentsScreening models(IN-VIVO) for analgesics and anti inflammatory agents
Screening models(IN-VIVO) for analgesics and anti inflammatory agents
 
Screening models of alzheimer’s disease
Screening models of alzheimer’s disease Screening models of alzheimer’s disease
Screening models of alzheimer’s disease
 
AT425.pptx
AT425.pptxAT425.pptx
AT425.pptx
 
Antipsychotic screening models
Antipsychotic screening modelsAntipsychotic screening models
Antipsychotic screening models
 
Acute oral Toxicity Up-Down Procedure 425 guideline
Acute oral Toxicity Up-Down Procedure 425 guidelineAcute oral Toxicity Up-Down Procedure 425 guideline
Acute oral Toxicity Up-Down Procedure 425 guideline
 
Acute toxicity studies-425
Acute toxicity studies-425Acute toxicity studies-425
Acute toxicity studies-425
 
Nootropics (M.Pharm)
Nootropics (M.Pharm)Nootropics (M.Pharm)
Nootropics (M.Pharm)
 

Más de Dr. Advaitha MV

Hematinics-maturation factors and Erythropoetin
Hematinics-maturation factors and ErythropoetinHematinics-maturation factors and Erythropoetin
Hematinics-maturation factors and ErythropoetinDr. Advaitha MV
 
Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)Dr. Advaitha MV
 
Pharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugsPharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugsDr. Advaitha MV
 
Screening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsScreening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsDr. Advaitha MV
 
Screening of local anaesthetics.advaith.
Screening of local anaesthetics.advaith.Screening of local anaesthetics.advaith.
Screening of local anaesthetics.advaith.Dr. Advaitha MV
 
General anaesthetics for pg copy
General anaesthetics for pg   copyGeneral anaesthetics for pg   copy
General anaesthetics for pg copyDr. Advaitha MV
 

Más de Dr. Advaitha MV (8)

Hematinics-maturation factors and Erythropoetin
Hematinics-maturation factors and ErythropoetinHematinics-maturation factors and Erythropoetin
Hematinics-maturation factors and Erythropoetin
 
Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)
 
Pharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugsPharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugs
 
Screening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsScreening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive Agents
 
Screening of local anaesthetics.advaith.
Screening of local anaesthetics.advaith.Screening of local anaesthetics.advaith.
Screening of local anaesthetics.advaith.
 
Sympathomimmetics
SympathomimmeticsSympathomimmetics
Sympathomimmetics
 
Vasodilators
VasodilatorsVasodilators
Vasodilators
 
General anaesthetics for pg copy
General anaesthetics for pg   copyGeneral anaesthetics for pg   copy
General anaesthetics for pg copy
 

Screening of Anxiolytics

  • 1. Screening of Anxiolytic Agents in Drug Discovery For MD Pharmacology Dr. Advaitha M V
  • 2. Anxiety Disorders • Definition : Anxiety is defined as a subjective sense of unease, dread, or foreboding. • It is the most prevalent psychiatric illnesses in the general community, are present in 15–20% of medical clinic patients.
  • 3. Preclinical anxiety models • The goal of anxiety models is to produce a form of abnormally elevated anxiety. • It should more closely resemble, by definition, the pathological nature of human anxiety disorders.
  • 4. • Anxiety models are Models that generate lasting or permanently heightened anxiety. This can be achieved by acutely or chronically subjecting animals to stressors before testing.  OR identifying genetic populations (inbred and selectively bred strains) or engineering mutant mice with innate anxiety-like phenotypes.
  • 5. • This approach has proven to be valuable for screening novel anxiolytics and testing the pharmaco selectivity of putative anxiolytics . • Emerging genetic technology is the optogenetics. It will be integral to future basic anxiety research.
  • 6. Optogenetics • It is the combination of genetic and optical methods to control specific events in targeted cells of living tissue in the millisecond timescale. • Optogenetic approaches have been used to map neural circuits in the amygdala that contribute to fear conditioning.
  • 7. • However , in general , it is only simple tests or assays which transiently evoke an anxiety-like behaviour in rhodents is commonly employed.
  • 8. The five main anxiety disorders with preclinical tests which resembles human anxiety • Generalized anxiety disorder (GAD)----MOST OF THE TESTS • Post-traumatic stress disorder (PTSD)……. FEAR CONDITIONED TESTS • Panic disorder………… ELEVATED T MAZE MODEL and MOUSE DEFENSE TEST BATTERY
  • 9. • Obsessive compulsive disorder (OCD)…… ??????? • Social anxiety disorder (SAD)…… SOCIAL INTERACTION MODEL
  • 10. PRECLINICAL EVALUATION OF ANXIOLYTICS • In-vitro Methods • In-vivo Methods • Our main focus here would be In-vivo.
  • 11. In- vitro methods • GABAA receptor binding • GABAB receptor binding • Benzodiazepine receptor: [3H]-flunitrazepam binding assay • Serotonin (5-HT1A) receptor: binding of [3H]-8- hydroxy-2-(di-n-propylamino)-tetralin ([3H]- DPAT) • Serotonin (5-HT1B) receptors in brain: binding of [3H]5-hydroxytryptamine ([3H]5-HT)
  • 12. The following parameters are calculated: • Total binding • Non-specific binding • Specific binding= total binding– non-specific binding.
  • 13. In Vivo Methods Validity • Face validity : A feature that is assessed (for a test or model of anxiety) by determining how closely the model or test resembles human anxiety symptoms . • Predictive validity : whether the model or test reliably responds to clinically efficacious anti- anxiety medications .
  • 14. • Construct validity : whether the degree to which the model or test recruits the same underlying neurobiology as implicated in human anxiety .
  • 15. Elevated plus –maze (EPM) test This has widely validated to measure anxiety to rodents
  • 16. Principle : • The test is based on the natural aversion of mice for open and elevated areas, as well as • natural aversion on their natural spontaneous exploratory behavior in novel environments. • The apparatus consists of open arms and closed arms, crossed in the middle perpendicularly to each other, and a center area.
  • 17. • Mice are given access to all of the arms and are allowed to move freely between them. Evaluation : • The number of entries into the open arms. (Entry an arm is defined as animal placing all four paws onto the arm. All tests are taped by using a video camera)
  • 18. • The time spent in the open arms are used as indices of open space-induced anxiety. Anxiolytic drugs specifically increase the number of entries into the open arms and the time spent there Anxiogenic drugs specifically decrease the entry
  • 19. • The total entries score and total distance are considered a Useful index of general activity. The percentages of entries and time spent in each arm constitute the index of primary anxiety
  • 20. Methodology : • The rats (200–250 g body weight) are housed in pairs for 10 days prior to testing in the apparatus. • During this time the rats are handled by the investigator on alternate days to reduce stress. • 6 rats are taken for each group.
  • 21. • Thirty min after i.p. administration of the test drug or the standard, the rat is placed in the center of the maze facing one of the enclosed arms. • Duration of test is 5 min where all data is collected.
  • 22. • Test should be conducted in sound proof room. • After each test, the maze is carefully cleaned up with wet tissue paper (10% ethanol solution)
  • 23. • Anxiolytic treatments do not by themselves increase exploration in the tests but they decrease the stress-induced inhibition of exploration behaviour
  • 25. • Crawley and goodwin (1980) • Mice and rats tend to explore novel environment ,but retreat from brightly lit open field. • In a two chambered system, where animal can freely move between brightly lit open field and dark corner, they show more crossings between two chambers and more locomotor activity after treatment with anxiolytics.
  • 26. Methodology • Test apparatus- light and dark chamber divided by photocell equipped zone. • Polypropylene animal cage 44x21x21 cm, darkened with black spray over on-third of surface. • Partition containing 13cm long x 5cm high opening separates the dark one third from bright two thirds of the cage
  • 27. • Cage rests on an animex activity monitor, which counts the locomotor activity. • Four sets of photocells across the partition, automatically counts movement through the partition and clocks time spent in light and dark
  • 28. • Naïve male mice or rats are placed in cage • Animals are treated 30 min before the experiment with test or vehicle intraperitoneally and are observed for 10 min. • Groups of 6-8 animals are used for each dose.
  • 29. • Evaluation: number of crossings through the partition between the light and dark chamber are compared with total activity counts during 10 min • Critical assessment of the method: anxiolytics like diazepam, pentobarbital, meprobamate, produce dose dependent increase in crossings • Test is relatively simple with no painful stimuli
  • 31. • Purpose and rationale : In an unfamiliar and brightly lit environment, the normal social interaction of rats ( sniffing, nipping, grooming) is suppressed. • Anxiolytics counteract this suppression.
  • 32. Procedure: • Male sprague-dawley rats (225-275g) are housed in groups of 5 animals • Apparatus: perspex open-topped box (51x51x 20cm) with 17x17cm marked areas on the floor. • One hour prior to the test, 2 naïve rats from separate housing cages are treated with test compound orally
  • 33. • They are placed into the box (with 60W bright illumination 17cm above) and their behaviour is observed over a 10 min period. • 2 types of behaviour can be noted: • Social interaction between the animals is determined by timing the sniffing of partner, crawling under or climbing over partner and following partner.
  • 34. • Exploratory motion is measured as the number of crossings of the lines marked on the floor of the test box. • Six pairs are used for each dose • Evaluation: values of treated partners are compared with the data from 6 pairs of untreated animals using single factor analysis of variance followed by Dunnett’s t-test
  • 36. • This test, originally designed by Hall on rats. • It consists of placing an animal in an unknown environment with surrounding walls, so as to observe a number of behaviour patterns, including The tendency to stay on the periphery of the field without entering the centre (called thigmotaxis and often interpreted as anxious behaviour)  level of defecation and urination.
  • 37. • The open field floor is divided into squares • Animals are tested individually, always being placed in the same position. • Duration of test is usually 5 min.
  • 38. • Higher levels of anxiety should mainly lead to decreases in the ratio ‘number of squares visited in centre/number of squares visited on periphery. • Anxiolytic agents should lead to increase in this ratio
  • 40. • This test is a well-known method used in rats, designed by Vogel et al. • Recently, this test has been reported to successfully detect anxiolytic-like action of diazepam . • In this test, thirsty animals gain water reward through a water spout, but at the expense of receiving a mild electric shock delivered to the tongue.
  • 41. • Licking in untreated/controls is suppressed due to the conflict. • Anxiolytics release this suppressed behaviour and decrease the conflict. • Diazepam and pentobarbital produces a significant anti-conflict effect, which means that - These drugs increases the number of electric shocks the mice received during the test session.
  • 42. • But drugs like baclofen, buspirone, chlorpromazine and also haloperidol did not produce anti-conflict effects.
  • 43. Resident-intruder aggression test Purpose and rational: To study the effects of drugs in a test for offensive aggression, the isolation-induced resident intruder aggression model in the rat. • Procedure: Sprague-Dawley rats weighing 250 to 450 g are housed in a light-dark (12L:12D)-, temperature (ca. 22°C)- and humidity (ca. 55%)-controlled room.
  • 44. Resident male rats (about 450 g) are tested in their home cages for aggression against a smaller (250 g) male intruder
  • 45. • They are treated by intraperitoneal injection of test drug or saline 15 min before the test. • The resident female is removed from the cage 30 min prior to the start of the test period. • After placing the intruder rat in the territorial cage, the behavior of the resident male is observed.
  • 46. • The time until the first attack (in seconds), number of attacks, and duration of each attack (in seconds) are recorded for the next 15 min by a blind observer. • Different behavioral elements are scored and grouped into 7 behavioral categories: offensive, exploration, social interest, inactivity, avoidance, body care, defense.
  • 47. • Evaluation: Paired and unpaired t-tests are used for comparisons of means of absolute values
  • 48. Other Anti- Aggressive tests • FOOT- SHOCK INDUCED AGGRESSION IN MICE • ISOLATION INDUCED AGGRESSION • MATERNAL AGGRESSION IN RATS
  • 49. Anticipatory anxiety in mice • Purpose and rationale: when group-housed mice are removed one by one from their home cage, the last mice removed have always higher rectal temperatures than those removed first.
  • 50. • This phenomenon is caused by anticipatory fear for an aversive event . • Increase in temperature prevented by prior treatment with diazepam and buspirone
  • 51. • Procedure: groups of 18 male albino swiss mice ( 25-30g) are housed in constant room temperature and relative humidity, for atleast 7days.
  • 52. • Test drugs or standard (diazepam) are administered orally in various doses to groups of 18 mice prior to the test. • Thirty min later, first 3 mice are removed from the cage, rectal temperature recorded by inserting a silicone lubricated thermistor probe (2mm diam) • Average temperature of these 3 mice is taken as basal value
  • 53. • Mice number 4 to 15 are simply removed and again returned to the cage. • Thereafter body temperature is determined in the remaining three animals. • The difference of the mean value of these mice and the basal values is calculated as increase. • Vehicle treated test groups display increases of 1.1 to 1.3 °C.
  • 54. • The mean increase values of treated groups are compared by ANOVA statistics with the controls .
  • 55. mCPP induced anxiety in rats • Purpose and rational: The metabolite of the antidepressant drug trazodone is 1- (3-chlorphenyl)piperazine (= mCPP). • It is 5- HT1C/1B/2C agonist. • It has been shown to be anxiogenic both in man and in rats.
  • 56. • The compound induces hypophagia and hypolocomotion, inhibits social interaction in rats, diminishes exploratory activity of rats in the open field test • In the light-dark box test induces hyperthermia • Antagonism against these symptoms has been proposed as a screening model for anxiolytic drugs.
  • 57. Novelty-suppressed feeding • Purpose and rational: Placing a hungry rat into an unfamiliar environment with access to food results in a suppression of feeding behavior relative to the condition when the test environment is familiar. • This effect has been termed hyponeophagia and occurs because of the novelty of the test environment.
  • 58. • The avoidance of novel foods is termed food neophobia • Both hyponeophagia and food neophobia have been assumed to measure emotionality or anxiety by eliciting a conflict situation arising from a fear of the novel setting and foods, and the drive to eat.
  • 59.
  • 60. Video downloads • http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2 762911/bin/jove-22-1088.flv • http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3 731199/bin/jove-77-4367.mov • http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3 727206/bin/jove-76-50324.mov